tiprankstipranks
Trending News
More News >
Otsuka Holdings Co (JP:4578)
:4578
Advertisement

Otsuka Holdings Co (4578) AI Stock Analysis

Compare
1 Followers

Top Page

JP:4578

Otsuka Holdings Co

(OTC:4578)

Rating:79Outperform
Price Target:
¥8,975.00
▲(11.60% Upside)
Otsuka Holdings Co's strong financial performance, characterized by robust revenue and profit growth, low leverage, and efficient cash flow generation, is the primary driver of its stock score. Technical indicators support a positive outlook, with the stock trading above key moving averages and showing bullish momentum. The valuation is attractive with a reasonable P/E ratio and a decent dividend yield, enhancing the stock's appeal.

Otsuka Holdings Co (4578) vs. iShares MSCI Japan ETF (EWJ)

Otsuka Holdings Co Business Overview & Revenue Model

Company DescriptionOtsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of oncology, cardiovascular system, renal system, digestive system, ophthalmology, diagnostics, and intravenous solutions, as well as medical devices businesses. It also provides EQUELLE, a product for women's health and beauty; BODYMAINTÉ Jelly, a conditioning food product; BODYMAINTÉ Drink, a drinkable-liquid; POCARI SWEAT, a drink; Calorie Mate, a nutritional food; OS-1, an oral rehydration solution; HINEX-R, a concentrated liquid diet; and Oronine H Ointment, a household antiseptic medicine. In addition, the company offers soft drinks, food products, and wines; chemicals; clinical testing and medical equipment; cosmetics; warehousing and transport services; analysis and measurement equipment; pharmaceutical intermediates; vehicle headlight testers; synthetic resin molded products; paper products; artificial turf; ceramic boards, ceramic walls, reliefs, terracotta, OT ceramics, and ceramic portraits and sign boards; functional films; stable isotopes; software and services to enhance management of mental healthcare systems; potassium titanate; polyolefin foams; spring and mineral water; industrial chemicals; hydrazine; insecticide and toiletry products; and adhesive tapes. Further, it operates a hotel. Otsuka Holdings Co., Ltd. was founded in 1921 and is based in Tokyo, Japan.
How the Company Makes MoneyOtsuka Holdings Co. makes money primarily through the sales of its pharmaceutical products, which constitute the largest portion of its revenue. The company develops and markets a range of prescription medications, notably in the fields of mental health, oncology, and cardiovascular health. Additionally, Otsuka generates revenue from its nutraceutical and consumer products divisions, which offer health and wellness products such as nutritional supplements and functional foods. The company leverages strategic partnerships and collaborations with other pharmaceutical and biotechnology companies to enhance its product offerings and market reach, further contributing to its revenue streams. Otsuka also invests in research and development to drive innovation and maintain a competitive edge in the healthcare market.

Otsuka Holdings Co Earnings Call Summary

Earnings Call Date:Jul 31, 2025
(Q2-2024)
|
% Change Since: |
Next Earnings Date:Oct 29, 2025
Earnings Call Sentiment Positive
The earnings call highlighted strong growth in revenue and business profit, driven by pharmaceutical and nutraceutical segments. Forecasts have been revised upward, and there is an acquisition to further enhance drug discovery capabilities. However, there were some negatives, such as impairment losses and a decrease in certain revenues. Overall, the positive aspects significantly outweigh the negatives, indicating a strong performance and optimistic outlook.
Q2-2024 Updates
Positive Updates
Significant Revenue and Business Profit Growth
Revenue increased by 17.0% to JPY 1,108.9 billion and business profit increased by 37.8% to JPY 213.6 billion year-on-year, led by strong sales in pharmaceutical and nutraceutical businesses.
Pharmaceutical Business Success
Revenue for the pharmaceutical business increased by 17.9% year-on-year to JPY 766.7 billion, achieving 108% of the initial plan, driven by Core 2 products, ABILIFY MAINTENA, and JYNARQUE.
Strong Nutraceutical Business Performance
Revenue in the nutraceutical business grew by over 20% to JPY 271.8 billion, with significant growth in all three categories: For Women's Health (56.9%), For Climate & Environmental Risk (13%), and For Healthier Life (25.5%).
Positive Outlook and Revised Forecast
Full year revenue forecast revised up by JPY 175 billion to JPY 2,315 billion, and business profit forecast increased by JPY 60 billion to JPY 390 billion.
Acquisition for Growth
Acquisition of a company in Boston for drug discovery technology announced, aiming to enhance growth and expand capabilities.
Negative Updates
Impairment Loss Impact
Operating profit was affected by an impairment loss on AVP-786, although net profit still increased by 5.1%.
Decrease in Upfront Milestone and Royalty Revenue
Total upfront milestone and royalty revenue decreased to JPY 41.8 billion due to lower sales milestone income compared to the previous year.
AVP-786 Development Discontinued
Development of AVP-786 for agitation associated with dementia due to Alzheimer's disease was discontinued for strategic reasons.
Company Guidance
During the Q2 2024 earnings call for 4578.T, the executives provided detailed guidance reflecting significant growth in both their pharmaceutical and nutraceutical segments. Revenue increased by 17.0% year-on-year to JPY 1,108.9 billion, while business profit surged by 37.8% to JPY 213.6 billion, driven primarily by strong sales of Core 2 pharmaceutical products like ABILIFY MAINTENA and JYNARQUE, and nutraceuticals, particularly in the For Women’s Health category. Despite an impairment loss on AVP-786, net profit rose by 5.1% due to finance income. The company also revised its full-year forecast upwards, with revenue now expected to reach JPY 2,315 billion and business profit JPY 390 billion. Nutraceutical revenue saw a notable increase, achieving over a 20% growth rate to JPY 271.8 billion, fueled by the expansion of products like Bonafide and Nature Made. Additionally, the company announced plans for share repurchases amounting to JPY 50 billion as part of their shareholder return policy.

Otsuka Holdings Co Financial Statement Overview

Summary
Otsuka Holdings Co exhibits strong financial health with impressive revenue and profit growth, a stable balance sheet with low leverage, and robust cash flow generation. Minor concerns include a slight increase in debt and cost pressures affecting EBIT margins.
Income Statement
85
Very Positive
Otsuka Holdings Co has demonstrated strong revenue growth, with a TTM revenue growth rate of 35.6%. The company maintains healthy profitability metrics, with a gross profit margin of 72.2% and a net profit margin of 14.7% in the TTM period. EBIT and EBITDA margins are also robust, indicating efficient operations. However, the slight decline in EBIT margin from the previous year suggests potential cost pressures.
Balance Sheet
78
Positive
The balance sheet of Otsuka Holdings Co is solid, with a low debt-to-equity ratio of 0.095, indicating conservative leverage. The return on equity is strong at 13.3%, reflecting effective use of shareholder funds. The equity ratio stands at a healthy level, showcasing financial stability. However, the slight increase in total debt over the period could be monitored for future leverage trends.
Cash Flow
82
Very Positive
Cash flow analysis reveals a significant improvement in free cash flow growth, with a TTM growth rate of 382.6%. The operating cash flow to net income ratio is stable, and the free cash flow to net income ratio is strong at 66.9%, indicating efficient cash conversion. The company has shown resilience in generating cash, supporting its operational and strategic initiatives.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.40T2.33T2.02T1.74T1.50T1.42T
Gross Profit1.73T1.67T1.41T1.17T1.00T983.08B
EBITDA515.32B452.62B224.20B266.93B244.25B273.37B
Net Income408.85B343.12B121.62B133.91B125.46B148.14B
Balance Sheet
Total Assets3.79T3.74T3.36T3.10T2.82T2.63T
Cash, Cash Equivalents and Short-Term Investments411.11B426.17B513.34B471.63B410.68B356.85B
Total Debt211.51B189.38B214.19B194.16B212.45B226.08B
Total Liabilities1.00T961.09B924.93B840.17B775.73B744.38B
Stockholders Equity2.72T2.73T2.39T2.23T2.01T1.85T
Cash Flow
Free Cash Flow340.80B225.28B168.56B104.06B115.71B134.96B
Operating Cash Flow434.32B354.64B283.23B211.85B228.86B232.84B
Investing Cash Flow-239.59B-268.27B-190.54B-81.58B-95.29B-99.86B
Financing Cash Flow-246.53B-186.89B-60.17B-95.47B-95.84B-104.93B

Otsuka Holdings Co Technical Analysis

Technical Analysis Sentiment
Positive
Last Price8042.00
Price Trends
50DMA
7288.74
Positive
100DMA
7081.79
Positive
200DMA
7587.98
Positive
Market Momentum
MACD
184.97
Positive
RSI
64.24
Neutral
STOCH
38.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4578, the sentiment is Positive. The current price of 8042 is above the 20-day moving average (MA) of 7879.95, above the 50-day MA of 7288.74, and above the 200-day MA of 7587.98, indicating a bullish trend. The MACD of 184.97 indicates Positive momentum. The RSI at 64.24 is Neutral, neither overbought nor oversold. The STOCH value of 38.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4578.

Otsuka Holdings Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
¥4.19T10.5515.51%1.62%10.17%226.18%
51
Neutral
$7.86B-0.33-41.57%2.23%23.26%-2.03%
$19.89B35.355.46%4.52%
$72.03B26.2921.48%3.76%
$44.65B22.2918.32%1.72%
$15.12B12.7713.71%4.53%
$47.48B45.091.99%4.83%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4578
Otsuka Holdings Co
8,042.00
-212.40
-2.57%
ALPMF
Astellas Pharma
11.15
-0.40
-3.46%
CHGCF
Chugai Pharmaceutical Co
42.25
-4.59
-9.80%
DSKYF
Daiichi Sankyo Company
23.55
-14.29
-37.76%
SGIOF
Shionogi & Co
17.96
3.05
20.46%
TKPHF
Takeda Pharmaceutical Co
27.45
0.99
3.74%

Otsuka Holdings Co Corporate Events

Otsuka Holdings Reports Strong H1 2025 Financial Results and Increases Dividend Forecast
Jul 31, 2025

Otsuka Holdings reported a significant increase in its consolidated financial results for the first half of 2025, with revenue rising by 6.5% and operating profit surging by 91.7% compared to the previous year. The company also announced a revision in its dividend forecast, increasing the annual dividend per share to 140 yen, reflecting confidence in its financial stability and growth prospects.

Otsuka Holdings Increases Interim and Annual Dividend Forecast
Jul 31, 2025

Otsuka Holdings Co., Ltd. announced an increase in its interim dividend to JPY 70.00 per share, up from the previous JPY 60.00, based on strong financial results for the first half of FY2025. Additionally, the company revised its annual dividend forecast, raising the year-end dividend to JPY 70.00 per share, resulting in a total annual dividend of JPY 140.00 per share, reflecting a JPY 20.00 increase. This decision underscores Otsuka’s stable dividend policy and its aim to enhance shareholder returns.

Otsuka Holdings Upgrades Financial Forecast for FY2025
Jul 28, 2025

Otsuka Holdings Co., Ltd. has revised its financial forecast for the first half of FY2025, projecting higher revenues and profits due to strong performance in its pharmaceutical and nutraceutical sectors. Despite the yen’s appreciation, key products like Rexulti and POCARI SWEAT have driven growth, and lower-than-expected expenses have contributed to the favorable outlook.

Otsuka Medical Devices Sells Stake in MicroPort to Boost Growth
Jul 25, 2025

Otsuka Medical Devices Co., Ltd., a subsidiary of Otsuka Holdings, has decided to sell a portion of its shares in MicroPort Scientific Corporation, resulting in MicroPort no longer being an equity-method affiliate of Otsuka. This strategic move aims to enhance sustainable growth and corporate value by reassessing the economic and qualitative significance of its holdings. The transaction involves multiple counterparties and is expected to impact Otsuka’s financial positioning and stakeholder relationships.

FDA Committee Reviews Otsuka and Lundbeck’s PTSD Treatment Application
Jul 21, 2025

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S have announced that the FDA’s Psychopharmacologic Drugs Advisory Committee has reviewed their supplemental New Drug Application for REXULTI (brexpiprazole) in combination with sertraline for treating PTSD in adults. The committee voted against the efficacy of this combination, which may impact the approval process and the companies’ market positioning in PTSD treatment.

Otsuka’s Sibeprenlimab Shows Promising Results in Phase 3 IgAN Study
Jun 6, 2025

Otsuka Holdings has announced promising interim results from its Phase 3 VISIONARY study, showing that its investigational drug sibeprenlimab achieved a significant 51.2% reduction in proteinuria for patients with Immunoglobulin A Nephropathy (IgAN). The study’s findings, presented at the European Renal Association Congress, highlight sibeprenlimab’s potential as a new treatment option, with a favorable safety profile and a novel mechanism targeting the disease’s immunologic pathogenesis. The drug has received Priority Review from the FDA, indicating its potential impact on the treatment landscape for this chronic kidney disease.

Otsuka’s Sibeprenlimab BLA Accepted by FDA for Priority Review
May 25, 2025

Otsuka Holdings Co., Ltd. announced that the FDA has accepted the Biologics License Application for sibeprenlimab, a monoclonal antibody for treating IgA nephropathy, with a priority review. This development could significantly impact Otsuka’s positioning in the nephrology market by offering a new treatment option that allows patients to self-administer the medication, potentially improving convenience and clinical outcomes for those with this chronic kidney disease.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 29, 2025